Residual cancer burden (RCB) after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes, according to data from a large meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium.
KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.
A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.
The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.
The addition of bevacizumab to capecitabine produced favorable efficacy and safety data for older patients with metastatic colorectal cancer.
